Aptahem appoints Ingela Hallberg as new CMO
Aptahem (publ) announces today that Ingela Hallberg has been appointed new Chief Medical Officer (CMO) in the company as of 1 June 2022. Ingela has long and solid experience from the pharmaceutical industry where she has held senior management positions within clinical research and development and medical affairs in a number of companies, both in regional and global roles, and within several different therapy areas. Four years ago she started her own company to support start-ups within life science to develop their products. Ingela is a medical doctor and previously worked within the area of cardiology, Sahlgrenska University Hospital, Gothenburg.
Ingela replaces Anders Bylock, who due to time limitations, can’t cover the increased activities required when Aptahem becomes a clinical company. Anders has been the company’s CMO since 2018 and is also, since 2017, chairman of the scientific advisory board. In connection with Ingela being appointed new CMO, Aptahem initiates the process in reviewing the scientific advisory board. The purpose is to broaden the advisory board to include more than scientific areas.
CMO Ingela Hallberg comments:
“Aptahem’s development project within sepsis is very interesting and I am looking forward to contributing with my broad medical experience from various therapy areas. I have for many years worked with development projects in global pharmaceutical companies and see Apta-1 as a very exciting and innovative drug candidate. Its unique mechanism of action makes it well suited to be tested as a future treatment for various serious inflammatory conditions, where sepsis will be an interesting first indication.”
CEO Mikael Lindstam comments:
”With Ingela as CMO, Aptahem gets an experienced leader who will focus on taking Aptahem into clinical phase. Her background from senior management positions in various global pharmaceutical companies provides valuable addition, as well as her broad experience from development projects within different therapy areas. I also want to thank Anders for his valuable contribution during the years, both as CMO and as scientific advisor.”
For further information:
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.